Chimeric Therapeutics Limited (ASX:CHM)
Australia · Delayed Price · Currency is AUD | Market Cap | 7.00M +8.0% |
| Revenue (ttm) | 9.75M +377.6% |
| Net Income | -18.79M |
| EPS | -0.76 |
| Shares Out | 51.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 302,416 |
| Average Volume | 89,508 |
| Open | 0.1450 |
| Previous Close | 0.1450 |
| Day's Range | 0.1350 - 0.1450 |
| 52-Week Range | 0.1000 - 0.9000 |
| Beta | 0.86 |
| RSI | 43.03 |
| Earnings Date | May 28, 2026 |
About Chimeric Therapeutics
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treat... [Read more]
Financial Performance
In fiscal year 2025, Chimeric Therapeutics's revenue was 12.68 million, an increase of 70.09% compared to the previous year's 7.46 million. Losses were -10.43 million, -16.76% less than in 2024.
Financial StatementsNews
Chimeric Therapeutics Transcript: EGM 2026
Shareholders approved major capital raising resolutions, a share consolidation, and discussed governance, capital allocation, and operational shifts to Australia. Key challenges included low retail participation, historical losses, and ASX compliance.
Chimeric Therapeutics Transcript: NWR Virtual Healthcare Conference
Two core cell therapy assets are advancing through late phase I, with strong manufacturing success and promising early clinical outcomes. Regulatory milestones and commercial interest are building, while industry trends show renewed momentum in cell therapy. Key updates on Dose Level 3 and further trial progress are expected soon.
Chimeric Therapeutics Transcript: Investor Update
Phase 1 trials for two cell therapy assets show strong safety, tumor shrinkage, and durable responses, with CHM CDH17 nearing Phase 2 and CHM CORN-K achieving over 50% response rates in AML. Commercial interest and regulatory progress are advancing, with key milestones expected in FY26.
Chimeric Therapeutics Transcript: Study Update
CHM 2101, a first-in-class CDH17 CAR-T therapy, is showing promising safety and early anti-tumor activity in phase one trials, with eight patients treated and no off-target effects observed. Fast track status and strong investigator enthusiasm support rapid development and commercial potential.
Chimeric Therapeutics Transcript: EGM 2025
The meeting covered major fundraising achievements, clinical trial progress, and significant cost reductions. All resolutions, including share and option issuances, were overwhelmingly supported by proxies, with final results to be released to the ASX.
Chimeric Therapeutics Transcript: Status Update
Active clinical trials are progressing, with promising early results in both CAR-T and NK cell programs. Financial stability has improved following recent capital raises, enabling continued patient recruitment and data generation. Regulatory and operational challenges persist, but strong partnerships and a lean, expert team support ongoing progress.